GTx, Inc. (NASDAQ:GTXI) VP Henry Patton Doggrell sold 4,965 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $56,253.45. Following the transaction, the vice president now owns 54,804 shares in the company, valued at approximately $620,929.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
GTx, Inc. (GTXI) opened at $11.15 on Thursday. GTx, Inc. has a twelve month low of $2.73 and a twelve month high of $13.35. The firm has a market capitalization of $240.19, a P/E ratio of -6.37 and a beta of 1.77.
GTX (NASDAQ:GTXI) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). analysts expect that GTx, Inc. will post -1.61 earnings per share for the current year.
GTXI has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on GTX in a report on Thursday, November 9th. They set a “buy” rating on the stock. Robert W. Baird initiated coverage on GTX in a report on Tuesday, November 21st. They set an “outperform” rating and a $17.00 price target on the stock. Finally, Zacks Investment Research downgraded GTX from a “hold” rating to a “sell” rating in a report on Wednesday.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/11/henry-patton-doggrell-sells-4965-shares-of-gtx-inc-gtxi-stock.html.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.